-
公开(公告)号：US20240309016A1
公开(公告)日：2024-09-19
申请号：US18606857
申请日：2024-03-15
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Mitsunori KONO , Yusuke SASAKI , Yuya OGURO , Zenichi IKEDA , Osamu KUBO , Masaki SETO , Toru YAMASHITA , Makoto KAMATA , Kenjiro SATO , Matthew Thomas REYNOLDS , Kazuaki TAKAMI , Asato KINA , Takafumi YUKAWA , Minoru NAKAMURA , Taku KAMEI , Hiroyuki KAKEI , Fumie YAMAGUCHI , Tomohiro OHASHI , Keiko KAKEGAWA , Takuto KOJIMA , Florian PÜNNER , Masataka MURAKAMI , Takahiko TANIGUCHI , Tatsuki KOIKE , Yuichi KAJITA , Yuhei MIYANOHANA , Kohei TAKEUCHI , Yoshiteru ITO , Norihito TOKUNAGA , Yasushi HATTORI , Eiji KIMURA , Martin Alexander PAWLICZEK , Marilena PIRA , Shuhei IKEDA , Noriyuki TEZUKA , Yoshikazu WATANABE , Kevin CURRAN , Nicolle DOERING , Maria HOPKINS , Ben JOHNSON , Andre KIRYANOV , Jon LAM , Sean MURPHY , Natasha O'ROURKE , Holly REICHARD , Paul TANIS , Yunlong ZHANG
IPC: C07D498/14 , A61K31/407 , A61K31/437 , A61P25/26 , C07D498/04
CPC classification number: C07D498/14 , A61K31/407 , A61K31/437 , A61P25/26 , C07D498/04
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):
wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号：US12091675B2
公开(公告)日：2024-09-17
申请号：US17296944
申请日：2019-07-15
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Hanspeter Rottensteiner , Werner Hoellriegl
IPC: C12N15/861 , A61K38/37 , A61K48/00 , C07K14/755
CPC classification number: C12N15/861 , A61K38/37 , A61K48/0083 , C07K14/755 , A01K2217/075 , A01K2227/105 , A01K2267/0381
Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A. In some embodiments, the present disclosure provides methods for dosing a hemophilia A patient with a polynucleotide, e.g., a codon-altered polynucleotide, encoding a Factor VIII polypeptide.
-
公开(公告)号：US12084515B2
公开(公告)日：2024-09-10
申请号：US17345033
申请日：2021-06-11
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Gregory P. Conley , Andrew Nixon , Daniel J. Sexton
CPC classification number: C07K16/40 , A61P27/02 , A61K9/0051 , A61K2039/505 , A61K2039/54 , C07K2317/30 , C07K2317/55 , C07K2317/76 , C07K2317/92
Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
-
公开(公告)号：US12084436B2
公开(公告)日：2024-09-10
申请号：US17426971
申请日：2020-01-29
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masahiro Ito , Takeshi Yamamoto , Keiko Kakegawa , Hideyuki Sugiyama , Tohru Miyazaki , Yasuyoshi Arikawa , Tomohiro Okawa , Jinichi Yonemori , Osamu Kubo , Akinori Toita , Takuto Kojima , Fumiaki Kikuchi , Minoru Sasaki , Misaki Homma , Yasuhiro Imaeda , Hironobu Maezaki , Shiinobu Sasaki , Ayumu Sato , Hirotaka Kamitani , Yasutomi Asano , Hironori Kokubo , Masato Yoshikawa
IPC: C07D413/10 , C07D271/06 , C07D413/14 , C07D417/14
CPC classification number: C07D413/10 , C07D271/06 , C07D413/14 , C07D417/14
Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I):
wherein each symbol is as described in the description, or a salt thereof.-
公开(公告)号：US12077522B2
公开(公告)日：2024-09-03
申请号：US17256330
申请日：2019-06-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Tatsuhiko Fujimoto , Koichiro Fukuda , Hiromichi Sugimoto , Kentaro Rikimaru , Yoshihiro Banno , Takahiro Matsumoto , Norihito Tokunaga , Yoshihide Tomata , Yuji Ishichi , Shogo Marui , Tsuneo Oda , Tohru Miyazaki , Yasutaka Hoashi , Yasushi Hattori , Yuichi Kajita , Yuhei Miyanohana , Tatsuki Koike
IPC: C07D401/14 , C07D211/56 , C07D405/14
CPC classification number: C07D401/14 , C07D211/56 , C07D405/14
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):
wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
Patent Agency Ranking
公开(公告)号：US20240216426A1
公开(公告)日：2024-07-04
申请号：US18557559
申请日：2022-04-27
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Nandhu SOBHANA , Alisha BOTHUN , Gil BENEZER , Shruti BADKAR , Rabi MISHRA , Hui-Hsin CHANG , Wanwen LI , Mansi SONI , Lan CAO , Xi SHl , Jane YEH , Mengyao LUO , Manoj GUPTA , Akito NAKAMURA , Doanh MAI , Mei Rosa NG
IPC: A61K35/15 , A61K39/00 , C07K14/54 , C07K14/705
CPC classification number: A61K35/15 , A61K39/463 , C07K14/54 , C07K14/5443 , C07K14/70575 , C07K2319/03 , C07K2319/30 , C12N2501/2315 , C12N2501/2321 , C12N2506/45 , C12N2510/00
Abstract: The present disclosure provides recombinant antigen presenting cells and methods of use thereof in the culture and expansion of immune cells ex vivo. In some aspects, immune cells expanded through co-culture of the recombinant antigen presenting cells disclosed herein are administered to a subject to treat a disease or condition in the subject, e.g., to treat a cancer.
-
公开(公告)号：US20240199613A1
公开(公告)日：2024-06-20
申请号：US18550486
申请日：2022-03-16
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Nikolaos PAPAIOANNOU , Jeremy Mark TRAVINS , Sarah Jocelyn FINK , John Mark ELLARD , Alastair RAE , Stuart Shane RANKIN , Robert Staurt Laurie CHAPMAN
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
-
公开(公告)号：US12005054B2
公开(公告)日：2024-06-11
申请号：US17320574
申请日：2021-05-14
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Zacharia Cheruvallath , Jason Green , Ben Johnson , Kristin Schleicher , Huikai Sun , Mingnam Tang
IPC: A61K31/4439 , A61K31/40 , A61K31/4355 , A61K31/438 , A61K31/4468 , A61K31/4545 , A61K31/497 , A61K31/501 , A61K31/506 , C07D207/14 , C07D211/58 , C07D401/12 , C07D401/14 , C07D403/12 , C07D491/048
CPC classification number: A61K31/4439 , A61K31/40 , A61K31/4355 , A61K31/438 , A61K31/4468 , A61K31/4545 , A61K31/497 , A61K31/501 , A61K31/506 , C07D207/14 , C07D211/58 , C07D401/12 , C07D401/14 , C07D403/12 , C07D491/048
Abstract: Disclosed are compounds of Formula 1,
stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6, R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.-
公开(公告)号：US20240173323A1
公开(公告)日：2024-05-30
申请号：US18264489
申请日：2022-02-04
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Akihiro OHASHI , Kenichi IWAI , Tadahiro NAMBU , Jie YU , Kurt ENG , Michael Joseph KURANDA
IPC: A61K31/519 , A61K31/454 , A61K31/502 , A61P35/00
CPC classification number: A61K31/519 , A61K31/454 , A61K31/502 , A61P35/00
Abstract: The present disclosure relates to the treatment of cancer using a combination therapy comprising Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, and one or more PARP inhibitors. Compound I.
-
公开(公告)号：US20240165118A1
公开(公告)日：2024-05-23
申请号：US18427579
申请日：2024-01-30
Inventor： Brendan Mark JOHNSON , Lynn SEELY , Paul N. MUDD, JR. , Susan WOLLOWITZ , Mark HIBBERD , Masataka TANIMOTO , Vijaykumar Reddy RAJASEKHAR , Mayukh Vasant SUKHATME
IPC: A61K31/519 , A61K9/00 , A61K31/513 , A61K31/565 , A61K31/57 , A61P15/00
CPC classification number: A61K31/519 , A61K31/513 , A61P15/00 , A61K9/0053 , A61K31/565 , A61K31/57
Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility.
-
-
-
-
-
-
-
-
-
Search Results
2064
records
(took 0.182 seconds)
